KPC variants conferring resistance to ceftazidime-avibactam in Pseudomonas aeruginosa strains

被引:0
|
作者
Hu, Yanyan [1 ]
Shen, Weiyi [1 ]
Lin, Di [2 ]
Wu, Yuchen [1 ]
Zhang, Yanyan [1 ]
Zhou, Hongwei [1 ]
Zhang, Rong [1 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Clin Lab, Hangzhou 310009, Peoples R China
[2] Ctr Dis Control & Prevet Shangcheng Dist, Hangzhou 310000, Zhejiang, Peoples R China
关键词
Pseudomonas aeruginosa; KPC variant; Ceftazidime/avibactam; Carbapenem-resistant; KLEBSIELLA-PNEUMONIAE; EMERGENCE;
D O I
10.1016/j.micres.2024.127893
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: This study aimed to characterize three KPC variants (KPC-33, KPC-100, and KPC-201) obtained from a clinical isolate of Pseudomonas aeruginosa (#700), along with two induced strains C109 and C108. Methods: Genomic DNAs of #700 (ST235), C109 (ST463), and C108 (ST1076) were sequenced using Illumina and Oxford Nanopore technologies. The transferability and stability of the plasmid was assessed through conjugation experiments and plasmid stability experiments, respectively. Minimum inhibitory concentrations of bacterial strains were determined using broth microdilution methods. In vitro induction was performed using ceftazidime-avibactam (CZA) at concentrations of 6/4 mu g/ml. Linear genomic alignments were visualized using Easyfig, and protein structure modeling of the novel KPC variant (KPC-201) was conducted using PyMol. Results: The plasmids carrying the KPC variants in the three CZA-resistant strains (C109, C108, and #700) had sizes of 39,251 bp (KPC-100), 394,978 bp (KPC-201), and 48,994 bp (KPC-33). All three plasmids belonged to the IncP-like incompatibility (Inc) groups, and the plasmid exhibited relatively high plasmid stability, KPC-33 and KPC-201-harboring plasmids were successfully transferred to the recipient strain P. aeruginosa PAO1(rifR). The genetic environments of the three bla(KPC) genes differed from each other. The mobile elements of the three bla(KPC) genes were as follows, TnAS1-IS26-Delta ISKpn27-bla(KPC-33)-ISKpn6-IS26, IS6-Delta ISKpn27-bla(KPC-100)-ISKpn6-IS26-Tn3-IS26, and IS6100-ISKpn27-bla(KPC-)201-ISKpn6-TnAS1. Notably, the length of Delta ISKpn27 upstream of the bla(KPC-33) and bla(KPC-100) genes were remarkably short, measuring 114 bp and 56 bp, respectively, deviating significantly from typical lengths associated with ISKpn27 elements. Moreover, the novel KPC variant, KPC-201, featured a deletion of amino acids LDR at positions 161-163 in KPC-3, resulting in a looser pocket structure contributing to its avibactam resistance. Conclusions: KPC-201, identified as a novel KPC variant, exhibits resistance to CZA. The presence of multiple mobile elements surrounding the bla(KPC-variant) genes on stable plasmids is concerning. Urgent preventive measures are crucial to curb its dissemination in clinical settings.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] First report of KPC variants conferring ceftazidime-avibactam resistance in Colombia: introducing KPC-197
    De la Cadena, Elsa
    Mojica, Maria Fernanda
    Rojas, Laura J.
    Castro, Betsy E.
    Garcia-Betancur, Juan Carlos
    Marshall, Steven H.
    Restrepo, Natalia
    Castro-Caro, Nancy Patricia
    Fonseca-Carrillo, Magalis
    Pallares, Christian
    Bonomo, Robert A.
    Villegas, Maria Virginia
    [J]. MICROBIOLOGY SPECTRUM, 2024, 12 (06):
  • [2] Performance of two immunochromatographic tests in detecting KPC variants conferring resistance to ceftazidime-avibactam
    de Lima, Aline Valerio
    Lima, Keila de Oliveira
    Rocha, Darlan Augusto da Costa
    Cappellano, Paola
    Boszczowski, Icaro
    Sampaio, Suely Carlos Ferreira
    Sampaio, Jorge Luiz Mello
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2024, 43 (06) : 1251 - 1253
  • [3] Complex evolutionary trajectories in vivo of two novel KPC variants conferring ceftazidime-avibactam resistance
    Tang, Chengkang
    Shen, Siquan
    Yang, Weiwei
    Shi, Qingyu
    Ding, Li
    Han, Renru
    Yin, Dandan
    Guo, Yan
    Zhu, Demei
    Hu, Fupin
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2024, 64 (03)
  • [4] Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants
    Poirel, Laurent
    Sadek, Mustafa
    Kusaksizoglu, Ayda
    Nordmann, Patrice
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2022, 41 (04) : 677 - 680
  • [5] Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants
    Laurent Poirel
    Mustafa Sadek
    Ayda Kusaksizoglu
    Patrice Nordmann
    [J]. European Journal of Clinical Microbiology & Infectious Diseases, 2022, 41 : 677 - 680
  • [6] A Selective Culture Medium for Screening Ceftazidime-Avibactam Resistance in Enterobacterales and Pseudomonas aeruginosa
    Sadek, Mustafa
    Poirel, Laurent
    Tinguely, Camille
    Nordmann, Patrice
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2020, 58 (09)
  • [7] Identification of a KPC Variant Conferring Resistance to Ceftazidime-Avibactam from ST11 Carbapenem-Resistant Klebsiella pneumoniae Strains
    Wu, Yuchen
    Yang, Xuemei
    Liu, Congcong
    Zhang, Yanyan
    Cheung, Yan Chu
    Chan, Edward Wai Chi
    Chen, Sheng
    Zhang, Rong
    [J]. MICROBIOLOGY SPECTRUM, 2022, 10 (02):
  • [8] Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas aeruginosa
    Daikos, George L.
    da Cunha, Clovis Arns
    Rossolini, Gian Maria
    Stone, Gregory G.
    Baillon-Plot, Nathalie
    Tawadrous, Margaret
    Irani, Paurus
    [J]. ANTIBIOTICS-BASEL, 2021, 10 (09):
  • [9] Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa
    Corbella, Laura
    Boan, Jorge
    San-Juan, Rafael
    Fernandez-Ruiz, Mario
    Carretero, Octavio
    Lora, David
    Hernandez-Jimenez, Pilar
    Ruiz-Ruigomez, Maria
    Rodriguez-Goncer, Isabel
    Tiago Silva, Jose
    Lopez-Medrano, Francisco
    Lizasoain, Manuel
    Villa, Jennifer
    Manuel Caro-Teller, Jose
    Aguado, Jose M.
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2022, 59 (02)
  • [10] Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa
    Nichols, Wright W.
    Stone, Gregory G.
    Newell, Paul
    Broadhurst, Helen
    Wardman, Angela
    MacPherson, Merran
    Yates, Katrina
    Riccobene, Todd
    Critchley, Ian A.
    Das, Shampa
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (11)